Watchlist Price Alert

Ascendis Pharma A/S (ASND)

NASDAQ: ASND · Real-Time Price · USD

162.72

-0.85 (-0.52%)

At close: May 30, 2025, 3:59 PM

162.84

0.07%

After-hours: May 30, 2025, 04:44 PM EDT

-0.52% (1D)

Bid	157.8
Market Cap	9.82B
Revenue (ttm)	368.7M
Net Income (ttm)	-341.67M
EPS (ttm)	-6.59
PE Ratio (ttm)	-24.69
Forward PE	87.98
Analyst	Buy

Ask	180
Volume	316,019
Avg. Volume (20D)	503,567
Open	163.50
Previous Close	163.57
Day's Range	162.69 - 165.66
52-Week Range	111.09 - 183.00
Beta	0.40

About ASND

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ASND

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ASND stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

+8.41%

Ascendis Pharma shares are trading higher after Ev... Unlock content with Pro Subscription

3 months ago

+12.96%

Ascendis Pharma shares are trading higher after the company reported better-than-expected Q4 financial results and authorized a share repurchase program worth $18.25 million.

News

1 week ago · accessnewswire.com

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Asce...

4 weeks ago · seekingalpha.com

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Scott Smith - Executive Vice President and Chief Financial Officer Jan Mikkelsen - President and...

1 month ago · zacks.com

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

1 month ago · seekingalpha.com

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Shares of ASND have fared well during recent market volatility and the downturn in the biotech sector. Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launc...

1 month ago · accessnewswire.com

Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting

TORONTO, ON / ACCESS Newswire / April 14, 2025 / Further to its press release on February 3, 2025, Ascendant Resources Inc. (the "Company" or "Ascendant") (TSX:ASND) announces that it has mailed and f...

2 months ago · zacks.com

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.